Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.75 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.75 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13122858 | 0.89 | SLC5A2 (0.65) | SLC5A2SLC5A1 | |
| SCHEMBL3412682 | 0.86 | SLC5A2 (0.56) | SLC5A2SLC5A1 | |
| SCHEMBL3410762 | 0.86 | SLC5A2 (0.56) | SLC5A2SLC5A1 | |
| SCHEMBL13107690 | 0.85 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC28A3 | |
| SCHEMBL3412686 | 0.84 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL3410769 | 0.84 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL3410768 | 0.84 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL4416370 | 0.84 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL13107696 | 0.81 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL3410749 | 0.77 | SLC5A2 (0.51) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816330-B2 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004188-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | URBANSKI MAUD | 2010-01-07 | — | — | US | disclosed |
| US-20090105165-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | URBANSKI MAUD | 2009-04-23 | — | — | US | disclosed |
| US-7511020-B2 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105165-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | GANAB, GCG, B3GAT3 | SLC5A2 16/4885SLC5A1 18/4885SLC28A3 1699/4885 |
| US-20100004188-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | GANAB, GCG, GANC | SLC5A2 18/4885SLC5A1 19/4885SLC28A3 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.